Management of IVIG-Induced Hyponatremia
Stop the IVIG infusion immediately and distinguish between pseudohyponatremia (hyperproteinemia-related) and true hyponatremia (dilutional or translocation-related) by measuring plasma osmolality, as this distinction is critical for determining appropriate treatment. 1, 2
Initial Assessment and Diagnosis
When hyponatremia develops during or after IVIG therapy, you must first determine the mechanism:
- Measure plasma osmolality immediately to differentiate pseudohyponatremia from true hyponatremia 2, 3
- Pseudohyponatremia occurs due to hyperproteinemia from IVIG, with normal plasma water sodium concentration and elevated osmolality 1, 3
- True hyponatremia results from sucrose-induced water translocation from intracellular to extracellular compartments, or from large volumes of dilute fluid infusion in patients with impaired free water excretion 2, 3
The FDA labeling explicitly warns that it is "clinically critical to distinguish true hyponatremia from pseudohyponatremia" because treating pseudohyponatremia with fluid restriction can lead to volume depletion, increased serum viscosity, and thrombosis risk 1
Treatment Based on Mechanism
For Pseudohyponatremia (Hyperproteinemia-Related):
- No specific sodium correction is needed as the plasma water sodium concentration is normal 1, 3
- Ensure adequate hydration to prevent volume depletion and hyperviscosity 1
- Monitor for thrombotic complications, as treatment aimed at decreasing free water can worsen outcomes 1
For True Hyponatremia:
Symptomatic or Severe Hyponatremia (sodium <130 mEq/L with symptoms):
- Administer 3% sodium chloride as 100-150 mL intravenous bolus for rapid correction if neurologic symptoms are present 4, 5
- Neurologic symptoms may include altered mental status, confusion, lethargy, nausea, vomiting, or headache 6, 7
- Monitor serum sodium frequently (every 2-4 hours initially) during correction 4, 5
- Correct at a rate not exceeding 8-10 mEq/L in 24 hours to avoid osmotic demyelination syndrome 4, 5
Asymptomatic Mild Hyponatremia (sodium 130-135 mEq/L):
- Implement fluid restriction of 500 mL/day initially, adjusted based on sodium levels 4
- Ensure adequate solute intake (salt and protein) 4
- Monitor serum sodium daily until stable 6
Evaluation for Contributing Factors
Patients developing true hyponatremia with IVIG should be evaluated for:
- Other sources of free water intake (IV medications containing free water, oral intake) 6
- Syndrome of inappropriate antidiuresis (SIAD) - check urine osmolality and urine sodium 6, 8
- Adrenal insufficiency - particularly in high-risk patients 6
Prevention Strategies for Future IVIG Administration
If IVIG therapy must be continued or restarted:
- Choose IVIG preparations with higher sodium content (0.9%) rather than trace sodium formulations, as these can worsen hyponatremia 9
- Administer at minimum effective dose and slowest infusion rate 1, 3
- Ensure adequate hydration before and during infusion 1, 3
- Avoid sucrose-containing IVIG products in patients with renal impairment, as sucrose causes osmotic injury and translocation hyponatremia 10, 2, 3
High-Risk Patient Considerations
Patients at increased risk for IVIG-related hyponatremia complications include those with:
- Pre-existing renal impairment 10, 3
- Advanced age (>65 years) 1, 10
- Diabetes mellitus 10, 3
- Volume depletion 1, 3
- Concurrent nephrotoxic medications or diuretics 10, 3
In these patients, monitor renal function (BUN, creatinine) and serum sodium before infusion and at appropriate intervals during therapy 1
Critical Pitfall to Avoid
The inverse correlation between sodium changes and creatinine changes (r = -0.308) indicates that hyponatremia severity often parallels the degree of IVIG-induced nephropathy 10. Therefore, always assess renal function concurrently when managing IVIG-induced hyponatremia, as acute renal failure may be present and influence both the hyponatremia mechanism and treatment approach 10, 3.